Vanessa Ravel1, Elani Streja1, Miklos Z Molnar2, Sepideh Rezakhani1, Melissa Soohoo1, Csaba P Kovesdy3, Kamyar Kalantar-Zadeh4, Hamid Moradi5. 1. Division of Nephrology and Hypertension, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine Medical Center, Orange, CA, USA. 2. Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, USA. 3. Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, USA Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, TN, USA. 4. Division of Nephrology and Hypertension, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine Medical Center, Orange, CA, USA Department of Medicine, UC Irvine School of Medicine, Irvine, CA, USA. 5. Division of Nephrology and Hypertension, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine Medical Center, Orange, CA, USA Nephrology Section, Long Beach VA Healthcare System, Long Beach, CA, USA.
Abstract
BACKGROUND: Liver disease is a common comorbid condition in maintenance hemodialysis (MHD) patients and may be associated with poor survival. The relationship between aspartate aminotransferase (AST) and survival has not yet been addressed in these patients. We hypothesized that higher AST level is associated with higher death risk in MHD patients. METHODS: A 5-year (January 2007-December 2011) cohort of 109 718 MHD patients was studied in the USA in dialysis clinics where AST was measured in at least 50% of all outpatients in the baseline calendar quarter. Survival models were adjusted for demographic variables, and available clinical and laboratory surrogates of malnutrition-inflammation complex, and cubic survival splines were plotted. RESULTS: A linear association existed between baseline serum AST levels and mortality. Increasing AST of >20 IU/L was incrementally and almost linearly associated with higher death risk at all levels of adjustment. In fully adjusted models, AST levels of ≥40 IU/L were associated with the highest risk of mortality (hazard ratio: 1.46, 95% CI: 1.38-1.54). Low AST levels (<15 IU/L) were associated with increased death risk only in fully adjusted models examining hepatitis C virus-positive patients. CONCLUSIONS: Higher AST level of >20 IU/L is incrementally associated with higher mortality in MHD patients whereas AST in the 15-20 IU/L range is associated with the greatest survival. These findings suggest that the assessment of liver function and improving liver disease may confer survival benefit to MHD patients.
BACKGROUND:Liver disease is a common comorbid condition in maintenance hemodialysis (MHD) patients and may be associated with poor survival. The relationship between aspartate aminotransferase (AST) and survival has not yet been addressed in these patients. We hypothesized that higher AST level is associated with higher death risk in MHD patients. METHODS: A 5-year (January 2007-December 2011) cohort of 109 718 MHD patients was studied in the USA in dialysis clinics where AST was measured in at least 50% of all outpatients in the baseline calendar quarter. Survival models were adjusted for demographic variables, and available clinical and laboratory surrogates of malnutrition-inflammation complex, and cubic survival splines were plotted. RESULTS: A linear association existed between baseline serum AST levels and mortality. Increasing AST of >20 IU/L was incrementally and almost linearly associated with higher death risk at all levels of adjustment. In fully adjusted models, AST levels of ≥40 IU/L were associated with the highest risk of mortality (hazard ratio: 1.46, 95% CI: 1.38-1.54). Low AST levels (<15 IU/L) were associated with increased death risk only in fully adjusted models examining hepatitis C virus-positive patients. CONCLUSIONS: Higher AST level of >20 IU/L is incrementally associated with higher mortality in MHD patients whereas AST in the 15-20 IU/L range is associated with the greatest survival. These findings suggest that the assessment of liver function and improving liver disease may confer survival benefit to MHD patients.
Authors: Jenny H D A van Beek; Marleen H M de Moor; Eco J C de Geus; Gitta H Lubke; Jacqueline M Vink; Gonneke Willemsen; Dorret I Boomsma Journal: Behav Genet Date: 2013-04-12 Impact factor: 2.805
Authors: Kamyar Kalantar-Zadeh; Ryan D Kilpatrick; Charles J McAllister; Loren G Miller; Eric S Daar; David W Gjertson; Joel D Kopple; Sander Greenland Journal: J Am Soc Nephrol Date: 2007-04-11 Impact factor: 10.121
Authors: Ben Schöttker; Rolf Jorde; Anne Peasey; Barbara Thorand; Eugène H J M Jansen; Lisette de Groot; Martinette Streppel; Julian Gardiner; José Manuèl Ordóñez-Mena; Laura Perna; Tom Wilsgaard; Wolfgang Rathmann; Edith Feskens; Ellen Kampman; Galatios Siganos; Inger Njølstad; Ellisiv Bøgeberg Mathiesen; Růžena Kubínová; Andrzej Pająk; Roman Topor-Madry; Abdonas Tamosiunas; Maria Hughes; Frank Kee; Martin Bobak; Antonia Trichopoulou; Paolo Boffetta; Hermann Brenner Journal: BMJ Date: 2014-06-17
Authors: Stanislas Werfel; Georg Lorenz; Bernhard Haller; Roman Günthner; Julia Matschkal; Matthias C Braunisch; Carolin Schaller; Peter Gundel; Stephan Kemmner; Salim S Hayek; Christian Nusshag; Jochen Reiser; Philipp Moog; Uwe Heemann; Christoph Schmaderer Journal: Sci Rep Date: 2021-04-29 Impact factor: 4.379
Authors: Ye Na Kim; Do Hyoung Kim; Ho Sik Shin; Sangjin Lee; Nuri Lee; Min-Jeong Park; Wonkeun Song; Seri Jeong Journal: PLoS One Date: 2020-12-10 Impact factor: 3.240